Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Oct, 2015 | Pages:
87 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Opium (Opioid) Addiction - Pipeline Review, H2 2015 Summary Global Markets Direct's, 'Opium (Opioid) Addiction - Pipeline Review, H2 2015', provides an overview of the Opium (Opioid) Addiction's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Opium (Opioid) Addiction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Opium (Opioid) Addiction and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Opium (Opioid) Addiction - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Opium (Opioid) Addiction and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Opium (Opioid) Addiction products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Opium (Opioid) Addiction pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to Buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Opium (Opioid) Addiction - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Opium (Opioid) Addiction pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents
2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Opium (Opioid) Addiction Overview 9 Therapeutics Development 10 Pipeline Products for Opium (Opioid) Addiction - Overview 10 Pipeline Products for Opium (Opioid) Addiction - Comparative Analysis 11 Opium (Opioid) Addiction - Therapeutics under Development by Companies 12 Opium (Opioid) Addiction - Therapeutics under Investigation by Universities/Institutes 13 Opium (Opioid) Addiction - Pipeline Products Glance 14 Late Stage Products 14 Clinical Stage Products 15 Early Stage Products 16 Opium (Opioid) Addiction - Products under Development by Companies 17 Opium (Opioid) Addiction - Products under Investigation by Universities/Institutes 18 Opium (Opioid) Addiction - Companies Involved in Therapeutics Development 19 Alkermes Plc 19 BioDelivery Sciences International, Inc. 20 Camurus AB 21 Celtic Pharmaceutical Holdings L.P. 22 Foresee Pharmaceuticals, LLC 23 Heron Therapeutics, Inc. 24 Indivior Plc 25 INSYS Therapeutics, Inc. 26 Omeros Corporation 27 Pfizer Inc. 28 Relmada Therapeutics, Inc. 29 Titan Pharmaceuticals, Inc. 30 Zynerba Pharmaceuticals, Inc. 31 Opium (Opioid) Addiction - Therapeutics Assessment 32 Assessment by Monotherapy Products 32 Assessment by Combination Products 33 Assessment by Target 34 Assessment by Mechanism of Action 36 Assessment by Route of Administration 38 Assessment by Molecule Type 40 Drug Profiles 42 (buprenorphine hydrochloride + naloxone hydrochloride) - Drug Profile 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 (samidorphan + buprenorphine hydrochloride) - Drug Profile 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 Buprenorphine Hemiadipate Hydrochloride - Drug Profile 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 buprenorphine hydrochloride - Drug Profile 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 buprenorphine hydrochloride - Drug Profile 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 buprenorphine hydrochloride - Drug Profile 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 buprenorphine hydrochloride depot - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 buprenorphine hydrochloride ER - Drug Profile 52 Product Description 52 Mechanism of Action 52 R&D Progress 52 buprenorphine hydrochloride long acting - Drug Profile 53 Product Description 53 Mechanism of Action 53 R&D Progress 53 buprenorphine hydrochloride SR - Drug Profile 54 Product Description 54 Mechanism of Action 54 R&D Progress 54 cannabidiol - Drug Profile 56 Product Description 56 Mechanism of Action 56 R&D Progress 56 Cannabidiol - Drug Profile 57 Product Description 57 Mechanism of Action 57 R&D Progress 57 FP-004 - Drug Profile 59 Product Description 59 Mechanism of Action 59 R&D Progress 59 naltrexone hydrochloride - Drug Profile 60 Product Description 60 Mechanism of Action 60 R&D Progress 60 naltrexone hydrochloride - Drug Profile 61 Product Description 61 Mechanism of Action 61 R&D Progress 61 OMS-405 - Drug Profile 62 Product Description 62 Mechanism of Action 62 R&D Progress 62 OMS-527 - Drug Profile 63 Product Description 63 Mechanism of Action 63 R&D Progress 63 PF-5006739 - Drug Profile 64 Product Description 64 Mechanism of Action 64 R&D Progress 64 samidorphan - Drug Profile 65 Product Description 65 Mechanism of Action 65 R&D Progress 65 Synthetic Peptides to Inhibit Mu Opioid, Delta Opioid and MRP-1 for Oncology and Morphine Addiction - Drug Profile 66 Product Description 66 Mechanism of Action 66 R&D Progress 66 TA-CD - Drug Profile 67 Product Description 67 Mechanism of Action 67 R&D Progress 67 Vaccine for Opium Addiction - Drug Profile 68 Product Description 68 Mechanism of Action 68 R&D Progress 68 Opium (Opioid) Addiction - Recent Pipeline Updates 69 Opium (Opioid) Addiction - Dormant Projects 77 Opium (Opioid) Addiction - Discontinued Products 78 Opium (Opioid) Addiction - Product Development Milestones 79 Featured News & Press Releases 79 Sep 28, 2015: Braeburn Announces FDA's Acknowledgment of Receipt of Probuphine NDA Resubmission; Agency Action Expected by February 27, 2016 79 Sep 03, 2015: Titan Pharmaceuticals To Present At Rodman & Renshaw 17th Annual Global Investment Conference 80 Aug 31, 2015: Titan Pharmaceuticals Announces Resubmission of the New Drug Application for Probuphine for the Maintenance Treatment of Opioid Addiction 80 Jun 08, 2015: Titan Pharmaceuticals Reports Positive Results From Phase 3 Study of Probuphine for Opioid Addiction 80 Jun 05, 2015: Titan Pharmaceuticals Schedules Conference Call to Review Results From Phase 3 Study of Probuphine for Opioid Addiction 82 Apr 15, 2015: Phase 3 Study Completion on Schedule for Late Q2, 2015 83 Apr 02, 2015: Relmada Therapeutics Set for Busy 2015 in Clinical Trials Developing Drugs for the Lucrative Pain Market 83 Mar 24, 2015: Relmada Therapeutics Receives Health Canada Clearance to Commence First Clinical Study for Novel Oral Formulations of Buprenorphine 84 Feb 24, 2015: Relmada Therapeutics Announces Filing of Clinical Trial Application in Canada for Novel Oral Formulations of Buprenorphine 85 Jan 06, 2015: Titan Pharmaceuticals to Present at 8th Annual OneMedForum 85 Appendix 86 Methodology 86 Coverage 86 Secondary Research 86 Primary Research 86 Expert Panel Validation 86 Contact Us 86 Disclaimer 87
List of Tables
Number of Products under Development for Opium (Opioid) Addiction, H2 2015 10 Number of Products under Development for Opium (Opioid) Addiction - Comparative Analysis, H2 2015 11 Number of Products under Development by Companies, H2 2015 12 Number of Products under Investigation by Universities/Institutes, H2 2015 13 Comparative Analysis by Late Stage Development, H2 2015 14 Comparative Analysis by Clinical Stage Development, H2 2015 15 Comparative Analysis by Early Stage Development, H2 2015 16 Products under Development by Companies, H2 2015 17 Products under Investigation by Universities/Institutes, H2 2015 18 Opium (Opioid) Addiction - Pipeline by Alkermes Plc, H2 2015 19 Opium (Opioid) Addiction - Pipeline by BioDelivery Sciences International, Inc., H2 2015 20 Opium (Opioid) Addiction - Pipeline by Camurus AB, H2 2015 21 Opium (Opioid) Addiction - Pipeline by Celtic Pharmaceutical Holdings L.P., H2 2015 22 Opium (Opioid) Addiction - Pipeline by Foresee Pharmaceuticals, LLC, H2 2015 23 Opium (Opioid) Addiction - Pipeline by Heron Therapeutics, Inc., H2 2015 24 Opium (Opioid) Addiction - Pipeline by Indivior Plc, H2 2015 25 Opium (Opioid) Addiction - Pipeline by INSYS Therapeutics, Inc., H2 2015 26 Opium (Opioid) Addiction - Pipeline by Omeros Corporation, H2 2015 27 Opium (Opioid) Addiction - Pipeline by Pfizer Inc., H2 2015 28 Opium (Opioid) Addiction - Pipeline by Relmada Therapeutics, Inc., H2 2015 29 Opium (Opioid) Addiction - Pipeline by Titan Pharmaceuticals, Inc., H2 2015 30 Opium (Opioid) Addiction - Pipeline by Zynerba Pharmaceuticals, Inc., H2 2015 31 Assessment by Monotherapy Products, H2 2015 32 Assessment by Combination Products, H2 2015 33 Number of Products by Stage and Target, H2 2015 35 Number of Products by Stage and Mechanism of Action, H2 2015 37 Number of Products by Stage and Route of Administration, H2 2015 39 Number of Products by Stage and Molecule Type, H2 2015 41 Opium (Opioid) Addiction Therapeutics - Recent Pipeline Updates, H2 2015 69 Opium (Opioid) Addiction - Dormant Projects, H2 2015 77 Opium (Opioid) Addiction - Discontinued Products, H2 2015 78
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
